Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses a randomized phase II trial to evaluate dosing strategies for regorafenib (Stivarga) in patients with refractory metastatic colorectal cancer.
Lower Dose of Trastuzumab Deruxtecan Shows Antitumor Activity in HER2+ mCRC
June 4th 2023Results from the DESTINY-CRC02 study showed that the lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512